Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
This article was originally published in The Tan Sheet
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy
You may also be interested in...
Food and supplement class action complaints could be slowed by legislation in Congress and by judges potentially de-emphasizing reliance on FDA interpretation of statutes, say lawyers during FDLI conference discussion.
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
High court refuses petitioners who requested the court review FDA's denial of a health claim linking saw palmetto to benign prostatic hyperplasia, law firm Emord & Associates says Oct. 12. Julian Whitaker, et al., filed the writ of certiorari earlier this year (1"The Tan Sheet" Jan. 19, 2004, p. 16)...